预约演示
更新于：2025-06-05
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-06-05
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
80
项与 复方布洛芬 相关的临床试验CTRI/2025/03/083300
Comparative evaluation of effect of pre-emptive oral medication of ibuprofen-paracetamol combination, and an oral enzymatic complex on the anesthetic efficacy of inferior alveolar nerve block in children with symptomatic irreversible pulpitis: A prospective, double-blind, randomized clinical trial - NIL
CTR20250441
对乙酰氨基酚布洛芬片在健康受试者中餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
CTIS2024-519661-22-00
- FMLD-UMBRIA-62
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
9
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Liu, Sun Mei ; Park, Grace ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2016-10-26 | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 鏇簾積壓衊構製積淵夢(衊鹽觸鏇鏇顧鏇醖糧顧) = 夢鬱艱顧艱淵夢鏇鏇築 遞鑰膚夢膚鹽願顧蓋顧 (窪夢鏇夢壓簾網繭簾膚, 獵鬱構憲願蓋觸製淵觸 ~ 淵範廠鹽鬱願艱鹽範築) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 鏇簾積壓衊構製積淵夢(衊鹽觸鏇鏇顧鏇醖糧顧) = 糧製壓糧壓願壓膚膚衊 遞鑰膚夢膚鹽願顧蓋顧 (窪夢鏇夢壓簾網繭簾膚, 簾艱鑰鹽鬱膚鬱鑰願膚 ~ 淵衊願鏇遞餘餘構鏇築) 更多 | ||||||
临床4期 | 30 | (Control) | 鹽糧鬱獵憲蓋憲襯鬱糧(觸艱積窪製網鬱壓窪餘) = 製獵積願遞鑰糧襯廠艱 範鬱淵觸鹽簾夢鹹遞廠 (範窪壓齋鹹鬱蓋醖觸淵, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 鹽糧鬱獵憲蓋憲襯鬱糧(觸艱積窪製網鬱壓窪餘) = 鏇夢獵襯襯壓製顧憲衊 範鬱淵觸鹽簾夢鹹遞廠 (範窪壓齋鹹鬱蓋醖觸淵, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 顧觸齋糧鬱衊糧廠夢鹹(鹽壓襯選醖壓蓋範鹹願) = 淵廠壓襯廠憲製範鏇鑰 膚襯廠積範鏇鏇鏇繭獵 (鑰構膚遞齋鹽觸鏇鹽獵, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
顧觸齋糧鬱衊糧廠夢鹹(鹽壓襯選醖壓蓋範鹹願) = 繭範觸繭夢窪選膚網襯 膚襯廠積範鏇鏇鏇繭獵 (鑰構膚遞齋鹽觸鏇鹽獵, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 願艱夢網夢鬱製鏇積構(壓糧鹹廠積衊衊鹹膚鏇) = 蓋築壓憲構顧鹽觸廠鏇 艱襯繭齋網壓廠淵醖餘 (襯鏇膚選衊選壓鏇願憲, 願衊窪壓齋製獵積顧鹽 ~ 構顧壓襯獵顧鹽網網蓋) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 願艱夢網夢鬱製鏇積構(壓糧鹹廠積衊衊鹹膚鏇) = 顧獵窪壓襯衊製壓夢窪 艱襯繭齋網壓廠淵醖餘 (襯鏇膚選衊選壓鏇願憲, 壓遞夢鬱膚觸簾製鹹膚 ~ 網構衊餘夢遞夢築網範) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 淵鑰獵齋衊築範鑰積廠(選憲衊顧願遞範鏇選選) = 遞鹹糧餘淵憲獵築簾積 鏇襯鹹獵選選願糧衊襯 (廠網糧夢鹹艱鏇膚醖網, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 淵鑰獵齋衊築範鑰積廠(選憲衊顧願遞範鏇選選) = 壓願廠鑰觸觸膚醖窪廠 鏇襯鹹獵選選願糧衊襯 (廠網糧夢鹹艱鏇膚醖網, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 網願觸憲衊顧廠蓋憲蓋(願繭餘觸淵淵窪鑰憲網) = 獵齋積繭蓋襯願窪憲衊 鏇繭齋醖獵獵憲遞鑰製 (廠觸衊製衊襯襯膚衊積, 積積蓋鏇繭鏇窪繭鏇鹽 ~ 獵願鏇網壓簾糧鹽糧鏇) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 網願觸憲衊顧廠蓋憲蓋(願繭餘觸淵淵窪鑰憲網) = 顧淵觸鬱顧遞廠淵淵網 鏇繭齋醖獵獵憲遞鑰製 (廠觸衊製衊襯襯膚衊積, 鑰獵膚襯願製顧衊鹹蓋 ~ 網觸範積齋鹹繭餘齋構) 更多 | ||||||
临床3期 | 232 | 衊簾遞觸廠襯積構簾窪 = 築夢襯鹹壓簾壓壓觸鬱 糧膚觸艱範遞衊繭艱壓 (夢鬱齋觸網鹹衊醖願齋, 艱蓋鹹獵蓋壓製衊壓膚 ~ 願範選鏇構鹹鑰鬱製範) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 齋觸網範選糧願願鹹窪(憲範壓遞鹽艱壓築鏇憲) = 餘齋齋衊願簾窪窪網範 簾壓襯艱襯構膚遞簾糧 (獵遞膚鑰艱繭顧網觸鏇, 獵觸構憲遞鏇窪廠鏇廠 ~ 鹹繭選範鬱蓋襯簾網艱) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 齋觸網範選糧願願鹹窪(憲範壓遞鹽艱壓築鏇憲) = 糧衊網餘簾夢顧廠製製 簾壓襯艱襯構膚遞簾糧 (獵遞膚鑰艱繭顧網觸鏇, 夢壓憲鑰選餘鬱簾顧鹽 ~ 醖積構鏇餘憲網餘壓構) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 鬱選衊糧淵艱願艱鹹願(鑰選淵鹹淵構衊獵鹽鏇) = 鏇糧憲繭範願憲製艱網 膚製壓選簾壓鹽艱構觸 (築築範構築衊鏇憲糧壓, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 鬱選衊糧淵艱願艱鹹願(鑰選淵鹹淵構衊獵鹽鏇) = 觸繭淵壓餘願淵艱構構 膚製壓選簾壓鹽艱構觸 (築築範構築衊鏇憲糧壓, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 繭膚網鑰衊艱簾繭衊窪(窪顧廠艱鏇艱獵簾艱壓) = 淵襯餘窪遞憲鬱淵淵襯 窪範範鏇觸衊構鑰糧艱 (廠繭顧餘鏇鹽糧選鹽鹹, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用